Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent
Food and Drug Administration approval of larotrectinib, it is now clinically important to …

Oncogenic fusions involving NTRK1, NTRK2, and NTRK3 with various partners are
diagnostic of infantile fibrosarcoma and secretory carcinoma yet also occur in lower …

Be prepared to diagnose and manage any condition you encounter in your practice! This
bestselling reference gives you direct access to a complete range of full-color clinical …

Background Mammary analogue secretory carcinoma (MASC) is a recently described
pathologic entity. We report the case of a patient with an initial diagnosis of salivary acinic …

Salivary gland neoplasms are a morphologically heterogenous group of lesions that are
often diagnostically challenging. In recent years, considerable progress in salivary gland …

Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an
oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer …

ETV6 gene abnormalities are well described in tumor pathology. Many fusion partners of
ETV6 have been reported in a variety of epithelial, mesenchymal, and hematological …

ETV6 gene abnormalities are well described in tumor pathology. Many fusion partners of
ETV6 have been reported in a variety of epithelial and hematological malignancies. In …

Chiosea SI, Griffith C, Assaad A & Seethala RR (2012) Histopathology 61, 387–394
Clinicopathological characterization of mammary analogue secretory carcinoma of salivary …

Mammary analogue secretory carcinoma of salivary gland origin (MASC) is a recently
described tumor resembling secretory carcinoma of the breast characterized by strong S …